Medicines | Horizonscan geneesmiddelen

Lisdexamfetamine ^IND Molindone

Blinatumomab

Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. ^IND Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy. ^IND

Dasatinib

Geïndiceerd voor de behandeling van volwassen patiënten met: nieuw gediagnosticeerde Philadelphiachromosoom-positieve (Ph+) chronische myeloïde leukemie (CML) in de chronische fase. CML in de chronische, acceleratie- of blastaire fase, die resistent of intolerant zijn voor eerder toegediende geneesmiddelen inclusief imatinib. Ph+ acute lymfoblastaire leukemie (ALL) en lymfoïde blasten CML die resistent of intolerant zijn voor eerder toegediende geneesmiddelen. Ook geïndiceerd voor de behandeling van pediatrische patiënten met: nieuw gediagnosticeerde Ph+ CML in de chronische fase (Ph+ CML-CP) of met Ph+ CML-CP die resistent of intolerant zijn voor eerder toegediende geneesmiddelen waaronder imatinib. Nieuw gediagnosticeerde Ph+ ALL in combinatie met chemotherapie. ^G Geïndiceerd voor de behandeling van volwassen patiënten met: nieuw gediagnosticeerde Philadelphiachromosoom-positieve (Ph+) chronische myeloïde leukemie (CML) in de chronische fase. CML in de chronische, acceleratie- of blastaire fase, die resistent of intolerant zijn voor eerder toegediende geneesmiddelen inclusief imatinib. Ph+ acute lymfoblastaire leukemie (ALL) en lymfoïde blasten CML die resistent of intolerant zijn voor eerder toegediende geneesmiddelen. Ook geïndiceerd voor de behandeling van pediatrische patiënten met: nieuw gediagnosticeerde Ph+ CML in de chronische fase (Ph+ CML-CP) of met Ph+ CML-CP die resistent of intolerant zijn voor eerder toegediende geneesmiddelen waaronder imatinib. Nieuw gediagnosticeerde Ph+ ALL in combinatie met chemotherapie. ^G

autologous anti-CD19-transduced CD3+ cells ^IND

Arimoclomol

Arseentrioxide

Geïndiceerd voor het induceren van remissie en consolidatie bij volwassen patiënten met: 1) nieuw gediagnosticeerde acute promyelocytaire leukemie (APL) met laag tot middelmatig risico (aantal witte bloedcellen ≤ 10 x 103/μl) in combinatie met all-trans-retinoïnezuur (ATRA), 2) recidiverende/refractaire acute promyelocytaire leukemie (APL) (tijdens een eerdere behandeling moet een retinoïde stof zijn toegediend en chemotherapie hebben plaatsgehad), gekenmerkt door de aanwezigheid van de translocatie t(15;17) en/of de aanwezigheid van het gen promyeolocitaire-leukemie-/retinoïnezuurreceptor-alfa (PML/RAR-alfa). ^G Geïndiceerd voor het induceren van remissie en consolidatie bij volwassen patiënten met: 1) nieuw gediagnosticeerde acute promyelocytaire leukemie (APL) met laag tot middelmatig risico (aantal witte bloedcellen ≤ 10 x 103/μl) in combinatie met all-trans-retinoïnezuur (ATRA), 2) recidiverende/refractaire acute promyelocytaire leukemie (APL) (tijdens een eerdere behandeling moet een retinoïde stof zijn toegediend en chemotherapie hebben plaatsgehad), gekenmerkt door de aanwezigheid van de translocatie t(15;17) en/of de aanwezigheid van het gen promyeolocitaire-leukemie-/retinoïnezuurreceptor-alfa (PML/RAR-alfa). ^G

Azacitidine Eprenetapopt Gilteritinib Glasdegib Guadecitabine Idasanutlin Imetelstat Iomab-B Pevonedistat Sapacitabine Venetoclax ^IND

Axicabtagene ciloleucel ^IND Ibrutinib ^IND Lisocabtagene maraleucel MB-CART2019.1 Polatuzumab vedotin Tafasitamab Tagraxofusp Zanubrutinib

Adrenaline Arachis hypogaea (pinda) allergenen (capsule) Arachis hypogaea (pinda) allergenen (pleister) Olopatadine / mometasone

Apixaban ^G Dabigatran ^G Dabigatran etexilate ^IND Ravulizumab ^IND Rivaroxaban ^IND

Beclometason/formoterol/glycopyrronium ^IND Budesonide / formoterol ^IND Dupilumab ^IND Fluticasone furoate / umeclidinium / vilanterol ^IND Indacaterol acetate/glycopyrronium bromide/mometasone furoate Indacaterol acetate/mometasone furoate Masitinib

Omalizumab

Aanvullende behandeling om de astmacontrole te verbeteren bij patiënten met ernstig persistent allergisch astma. ^BS Aanvullende behandeling om de astmacontrole te verbeteren bij patiënten met ernstig persistent allergisch astma. ^BS Aanvullende behandeling om de astmacontrole te verbeteren bij patiënten met ernstig persistent allergisch astma. Ook voor de behandeling van chronische idiopathische urticaria. ^BS

Tezepelumab

Amoxicilline / omeprazol / rifabutin Bedaquiline ^IND Ceftaroline fosamil ^IND

Ceftazidime / avibactam

Zavicefta is indicated in adults and children aged 3 months and older and adolescents for the treatment of the following infections in adults with Complicated intra-abdominal infection (cIAI), Complicated urinary tract infection (cUTI), including pyelonephritis, Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP). ^IND Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, the currently approved indications for complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) and hospital-acquired pneumonia, including ventilator-associated pneumonia. ^IND

Ceftobiprole Delafloxacin ^IND Delamanid ^IND Iclaprim

Imipenem / cilastatin / relebactam

Recarbrio is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults. Treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults. ^IND

Lefamulin Liposomaal amikacine Obiltoxaximab Ozenoxacine Pretomanid SER 109 Tebipenem Tedizolid ^IND

Lumateperone

Atezolizumab

Extension of indication to include, in combination with platinum-based chemotherapy, first-line treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) for Tecentriq. ^IND Adjuvant treatment after surgical resection of high-risk muscle-invasive bladder cancer (MIBC). ^IND

Avelumab ^IND Durvalumab ^IND Enfortumab vedotin Erdafitinib Nivolumab ^IND Oportuzumab monatox

Adalimumab ^IND Etrolizumab ^IND Filgotinib Mirikizumab Ozanimod ^IND Remestemcel-L ^IND Risankizumab ^IND Tenapanor Upadacitinib ^IND

Autologous glioma tumor cell lysates Vocimagene amiretrorepvec

Abemaciclib ^IND Alpelisib Atezolizumab ^IND Balixafortide Efbemalenograstim alfa Margetuximab Neratinib ^IND Olaparib ^IND Paclitaxel

Pembrolizumab

Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease. ^IND Triple Negative Breast Cancer - Neoadjuvant and adjuvant. ^IND

Pertuzumab / trastuzumab Sacituzumab govitecan Tesetaxel

Trastuzumab deruxtecan

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Patients with HER2 low, unresectable, and/or metastatic breast cancer previously treated with 1-2 prior lines of chemotherapy in the metastatic setting and has progressed on, and would no longer benefit from, endocrine therapy. ^IND Treatment of adult patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane 2L. ^IND

Trastuzumab duocarmazine Trastuzumab emtansine ^IND Tucatinib

Acalabrutinib

Calquence as monotherapy is indicated for the treatment of adult patients with relapsed/refractory CLL (chronic lymphocytic leukemia). Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

Duvelisib

Ibrutinib

Extension of indication to the existing chronic lymphocytic leukaemia (CLL) indication to include combination use with obinutuzumab for the treatment of adult patients with previously untreated CLL. ^IND Extension of indication in chronic lymphocytic leukaemia (CLL) to add combination with rituximab as follows; Ibrutinib in combination with rituximab or obinutuzumab for the treatment of adult patients with previously untreated CLL (Young and Fit). ^IND

Moxetumomab pasudotox Ublituximab Venetoclax ^IND ibrutinib ^IND

Beclometason/formoterol/glycopyrronium Formoterol / glycopyronium / budesonide Revefenacin

Avacopan Macitentan ^IND Sutimlimab

Cemiplimab ^IND Lifileucel

Eflornithine / sulindac Nivolumab ^IND Tegafur / gimeracil / oteracil ^IND

Bamocaftor / tezacaftor / ivacaftor

Elexacaftor / tezacaftor / ivacaftor

Kaftrio is indicated in a combination regimen with ivacaftor 150mg tablets for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene Uitbreiding van Kaftrio in combinatie met ivacaftor voor patienten met tenminste één F508del mutatie naar de leeftijd vanaf 6 jaar (uitbreiding voor 6 tot 11 jarigen)

Ivacaftor ^IND Lumacaftor / ivacaftor ^IND Tezacaftor / ivacaftor ^IND

Aducanumab

Leuco-methylthioninium

Alzheimer’s disease, mild-to-moderate. Dementia, behavioural variant frontotemporal.

Brexanolone Bupropion/dextromethorphan

Esketamine

Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant major depressive disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode. Extension of indication to include a new indication for SPRAVATO® (esketamine nasal spray) co-administered with oral antidepressant therapy in adults with a moderate to severe episode of Major Depressive Disorder (MDD), as acute short term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency. ^IND

Zuranolone

Bexagliflozine Dapagliflozine ^IND Dasiglucagon Exenatide Finerenone Glucagon Insulin aspart ^BS Insulin lispro (ultra rapid formulation) Polyethylene glycol loxenatide Reparixin Sotagliflozine ^IND Teplizumab Tirzepatide

Golodirsen

Brivaracetam ^IND Cannabidiol ^IND Cenobamate

Fenfluramine

Fintepla is indicated for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older. Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome ^IND

Ganaxolone Lacosamide ^IND Perampanel ^IND

Aflibercept ^BS Aganirsen Avacincaptad pegol Bevacizumab-vikg Brolucizumab ^IND Faricimab Latanoprostene bunod Lenadogene nolparvovec Netarsudil / latanoprost Perfluorohexyloctane Polihexanide

Ranibizumab

Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS Treatment of neovascular age-related macular degeneration (AMD)

Reproxalap Sepofarsen Timrepigene emparvovec Voretigene neparvovec

Ibrexafungerp ^IND Posaconazol ^IND Rezafungin

Atazanavir / cobicistat Cabotegravir Etravirine ^IND Fostemsavir Lenacapavir

Durvalumab

Squamous cell carcinoma of the head and neck, 1L PDL 1 in combination with tremelimumab. ^IND Squamous cell carcinoma of the head and neck, 1L PDL 1. ^IND

Leukocyte interleukin Pembrolizumab ^IND

Eptinezumab Erenumab Fremanezumab Galcanezumab Lasmiditan Meloxicam/rizatriptan Rimegepant

Brimapitide Pioglitazone

Eptacog beta (activated) Etranacogene dezaparvovec FLT180a Fibrinogen Fidanacogene elaparvovec

Pembrolizumab ^IND

Drospirenon / estetrol, monohydraat Levoketoconazole Linzagolix Lonapegsomatropin Octreotide Osilodrostat Relugolix ^IND Relugolix / estradiol / norethisteronen Somapacitan Somatrogon Tenapanor ^IND

Axicabtagene ciloleucel ^IND Copanlisib

Ibrutinib

Follicular lymphoma (FL), relapsed / refractory. ^IND Marginal zone lymphoma (MZL), relapsed / refractory. ^IND

Umbralisib

Human normal immunoglobulin ^IND

Avelumab ^IND Cabozantinib ^IND Lenvatinib ^IND

Pembrolizumab

Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy. ^IND Extension of indication for Keytruda to include in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC). ^IND

Tivozanib ^IND

Asciminib

Bempedoic acid Bempedoic acid / ezetimibe Evinacumab Evolocumab ^IND Inclisiran

Atezolizumab ^IND

Durvalumab

Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. ^IND In combination with tremelimumab in patients with HCC not eligible for locoregional therapy (1L). ^IND

Pembrolizumab ^IND Pemigatinib Tremelimumab

Cenicriviroc Givosiran Maralixibat Obeticholic acid ^IND Odevixibat Seladelpar

Amivantamab Atezolizumab ^IND Avelumab ^IND Brigatinib ^IND Capmatinib

Cemiplimab

Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. ^IND Cemiplimab wordt onderzocht als eerstelijns behandeling in combinatie met chemotherapie voor volwassen patiënten met lokaal gevorderd of gemetastaseerde plaveiselcel en niet-plaveiselcel NSCLC (stadium IIIB/C-IV) onafhankelijk van PD-L1 expressie. ^IND

Durvalumab

Non-small cell lung cancer (NSCLC) stage IV, in combination with tremelimumab and chemo,1L. Non-small cell lung cancer (NSCLC) stage IV, in combination with chemo, 1L. ^IND Imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). ^IND 1L advanced NSCLC ^IND Completely resected NSCLC ^IND Lokaal gevorderd, niet-resectabel NSCLC (stadium III) ^IND

Ensartinib Entrectinib Lorlatinib ^IND Lurbinectedin Nivolumab ^IND Osimertinib ^IND Pralsetinib Selpercatinib Sotorasib Tedopi Tepotinib Trilaciclib

Benralizumab ^IND Gefapixant

Mepolizumab

Extension of indication to include Eosinophilic Granulomatosis with Polyangiitis (EGPA) to Nucala ^IND Extension of indication to include Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for Nucala (mepolizumab). ^IND

Nintedanib

Ofev is indicated in adults for the treatment of systemic sclerosis associated interstitial lung disease. ^IND Ofev is indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases with a progressive phenotype. ^IND

Pirfenidone ^IND

Hypericin

Nivolumab ^IND

Arimoclomol Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene Avalglucosidase alfa Betaine ^G Cipaglucosidase alfa / Miglustat Elivaldogene autotemcel Hydrocortison Kaliumcitraat / kaliumwaterstofcarbonaat Lonafarnib Migalastat ^IND Olipudase alfa Pegunigalsidase alfa Pegvaliase Reloxaliase Sapropterin ^G Sodium zirconium cyclosilicate Trientine Triheptanoin Veverimer Volanesorsen ^IND

Belantamab mafodotin

Blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Multiple Myeloma 3L ^IND

Carfilzomib ^IND

Daratumumab

Extension of indication to extend the existing therapeutic indication for daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). ^IND Extension of indication to extend the existing therapeutic indication for daratumumab in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). ^IND Darzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. ^IND In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy. ^IND Subcutaneous formulation indicates for Relapsed or Refractory Multiple Myeloma. ^IND Multipel myeloom frontline behandeling in cpmbinatie met VRd voor patiënten die niet in aanmerking komen voor een ASCT. ^IND Multipel myeloom frontline onderhoudsbehandeling na DVTd, voor patiënten die in aanmerking komen voor een ASCT. ^IND Smouldering multipel myeloom. ^IND

Idecabtagene vicleucel

Isatuximab

Sarclisa is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ^IND In Combination With Bortezomib, Lenalidomide and Dexamethasone (Isa VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant. ^IND

JNJ-4528 Lenalidomide ^IND Pomalidomide ^IND

Selinexor

Nexpovio is indicated in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ^IND

Diroximel fumarate Fampridine ^G Fingolimod ^G Masitinib Natalizumab Ofatumumab Ponesimod Siponimod Teriflunomide ^IND

Bidridistrogene xeboparvovec Sugammadex ^G

AMDC-USR Mexiletine HCl

Fedratinib

Selumetinib Surufatinib

Cannabidiol gel/intradermaal Eladocagene exuparvovec Inebilizumab Remimazolam Ronopterin Satralizumab Tiratricol

131I-omburtamab Dostarlimab Durvalumab ^IND Entrectinib Glucarpidase Ivosidenib ^IND Larotrectinib Lenvatinib ^IND Lipegfilgrastim ^IND NY-ESO-1 autologous engineered TCR-T cells

Nivolumab

Opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. ^IND Extension of indication to include adjuvant treatment of adult patients with resected oesophageal, or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy for OPDIVO. ^IND

Pembrolizumab

Keytruda as monotherapy is indicated for the first‑line treatment of metastatic microsatellite instability‑high (MSI‑H) or mismatch repair deficient (dMMR) colorectal cancer in adults. ^IND Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma in adults who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation. ^IND Keytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 10. ^IND Women With Persistent, Recurrent, or Metastatic Cervical Cancer (1L). ^IND

Retifanlimab Selinexor ^IND Sodium thiosulfate

Anakinra ^IND Baricitinib ^IND Belatacept ^IND Belimumab ^IND Berotralstat Elobixibat Forigerimod Icatibant ^G Imlifidase MDR-101 Mavorixafor RP-L201 Teprasiran Teprotumumab Triamcinolone Voclosporin

Ibrutinib ^IND Zanubrutinib

Allogenic immunomodulatory progenitor cells Apabetalon

Dapagliflozine

Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. ^IND Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). ^IND

Emiplacel

Empagliflozine

Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). ^IND Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. ^IND

Icosapent ethyl Omecamtiv mecarbil Rilonacept Tafamidis ^IND

Ticagrelor

Extension of indication to include, in co administration with acetylsalicylic acid (ASA), the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) without a history of myocardial infarction who have undergone percutaneous coronary intervention (PCI). ^IND Extension of indication to include, in co-administration with acetylsalicylic acid (ASA), the prevention of stroke in adult patients with acute ischaemic stroke or transient ischaemic attack (TIA) in the previous 24 hours. ^IND

Udenafil Valsartan / sacubitril ^IND Vericiguat

Autologous human chondrocytes in vitro expanded Burosumab ^IND Dapagliflozine ^IND Diazoxide choline (controlled-release tablet) Elamipretide Fexapotide Liraglutide ^IND Lumasiran Nolasiban Romosozumab Semaglutide ^IND Setmelanotide ^IND Sofpironium bromide Spheroids of human autologous matrix-associated chondrocytes ^IND Vosoritide

Avatrombopag

Betibeglogene autotemcel

Zynteglo is geïndiceerd voor gebruik bij patiënten in de leeftijd van 12 jaar en ouder met transfusie-afhankelijke β-thalassemie (transfusion-dependent β-thalassaemia - TDT) die geen β0/β0-genotype hebben, voor wie transplantatie van hematopoëtische stamcellen (HSC) gepast is, maar geen humaan leukocytenantigeen (HLA)-compatibele gerelateerde HSC-donor beschikbaar is. Behandeling van patiënten jonger dan 12 jaar met transfusie-afhankelijke β-thalassemie (TDT) die geen β0/β0-genotype hebben en voor wie hematopoïetische stamceltransplantatie (HSC) gepast is, maar voor wie geen humaan leukocyt antigeen (HLA)-compatibele verwante HSC-donor beschikbaar is. ^IND Behandeling van patiënten met transfusie-afhankelijke β-thalassemie (TDT) die een β0 mutatie op beide allelen van het β-globuline (HBB) hebben, en voor wie hematopoïetische stamceltransplantatie (HSC) gepast is, maar voor wie geen humaan leukocyt antigeen (HLA)-compatibele verwante HSC-donor beschikbaar is ^IND

Crizanlizumab Daprodustat Deferasirox ^G

Eculizumab

Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) ^BS Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) ^BS Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). ^BS

Efgartigimod Ferumoxytol Hydroxycarbamide ^IND Luspatercept ^IND Mepolizumab ^IND Mitapivat Pegcetacoplan RP-L102

Ravulizumab

Treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) in patients with haemolysis with clinical symptom(s) indicative of high disease activity and in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. Extension of indication to include treatment of paediatric patients with paroxysmal nocturnal haemoglobinuria (PNH) for Ultomiris. ^IND

Romiplostim ^IND Roxadustat Thrombomodulin alfa Vadadustat Voxelotor

Dexmedetomidine

Niraparib ^IND Olaparib ^IND Veliparib

Bupivacaine Bupivacaine / meloxicam Fasinumab Lidocaïne Neridronic Acid SDN037

Tanezumab

Treatment of moderate to severe chronic pain associated with OA of the hip or knee in adult patients for whom treatment with NSAIDs and/or any opioid is ineffective, not tolerated or inappropriate Chronic Low Back Pain for ≥3 months ^IND

Eryaspase (Asparaginase) Olaparib ^IND

Amantadine Apomorphine Istradefylline Levodopa / carbidopa

177Lu-PSMA-617 ^IND

Abiraterone

Abiraterone / apalutamide Apalutamide ^IND Cabazitaxel ^G DCVAC

Darolutamide

Nubeqa is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Adult men with metastatic hormone senstive prostate cancer (mHSPC) in combination with docetaxel en ADT. ^IND

Enzalutamide ^IND Masitinib

Olaparib

Monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. (only BRCA mutations included in the indication). ^IND Treatment in combination with abiraterone acetate in patients with metastatic Castration-resistant Prostate Cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting). ^IND

Relugolix

Anifrolumab Guselkumab ^IND Olokizumab Risankizumab ^IND Sarilumab ^IND Tocilizumab ^BS

Tofacitinib

Treatment of active polyarticular course juvenile idiopathic arthritis patients 2 years of age and older. ^IND Treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. ^IND

Upadacitinib

Rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. ^IND Rinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Rinvoq may be used as monotherapy or in combination with methotrexate. ^IND

Onasemnogene abeparvovec Risdiplam

Lurasidone ^IND Olanzapine / samidorphan

Atezolizumab ^IND

Cemiplimab

Monotherapy treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. Libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI). ^IND

Darleukin fibromun Lifileucel Relatlimab Seviprotimut-L Tavokinogene telseplasmid

Abrocitinib Beremagene geperpavec Berkenschorsextract Bimekizumab Clascoterone Crisaborole Difelikefalin Dupilumab ^IND Glycopyrronium tosylate Lebrikizumab Nemolizumab Regenerative Skin Tissue Risankizumab ^IND Ruxolitinib ^IND Secukinumab ^IND Spesolimab

Tapinarof

Adult Plaque Psoriasis Atopische dermatitis

Tirbanibulin Tralokinumab Upadacitinib ^IND

Daridorexant JZP-258 Lemborexant Natriumoxybaat ^IND Natriumoxybaat controlled release Pitolisant ^IND Tasimelteon ^IND

Inolimomab Itacitinib Motixafortide Narsoplimab Omidubicel Remestemcel-L Rimiducid Rivogenlecleucel Ruxolitinib ^IND Tabelecleucel Thiotepa ^G autologous anti-CD19-transduced CD3+ cells

Avapritinib Nivolumab ^IND Ripretinib Rivoceranib Trastuzumab deruxtecan ^IND

Selpercatinib

Patients With RET-Mutant Medullary Thyroid Cancer. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Vibegron

APN01 Baloxavir marboxil Bamlanivimab/ etesevimab Baricitinib ^IND Bulevirtide Casirivimab/imdevimab Dapagliflozine ^IND Elbasvir / grazoprevir ^IND Glecaprevir / pibrentasvir ^IND Lonafarnib Maribavir Nirsevimab Regdanvimab

Remdesivir

Veklury is geïndiceerd voor de behandeling van coronavirus disease 2019 (COVID-19) bij volwassenen en jongeren (vanaf 12 jaar die minstens 40kg wegen) met pneumonie die aanvullende zuurstof nodig hebben. Extension of indication to include treatment of adults with pneumonia not requiring supplemental oxygen (moderate COVID-19). ^IND

Sotrovimab Tecovirimat Zanamivir

Published on 8 June 2021

ADHD

ALL

Blinatumomab

Dasatinib

ALS

AML / MDS

Arseentrioxide

Aggressive non-Hodgkin’s lymphoma

Allergy

Antithrombotic medications

Asthma

Omalizumab

Bacterial infections

Ceftazidime / avibactam

Imipenem / cilastatin / relebactam

Bipolar disorder

Bladder cancer

Atezolizumab

Bowel diseases

Brain cancer

Breast cancer

Pembrolizumab

Trastuzumab deruxtecan

CLL

Acalabrutinib

Ibrutinib

COPD

Cardiovascular diseases

Cervical cancer

Colon cancer

Cystic fibrosis

Elexacaftor / tezacaftor / ivacaftor

Dementia

Leuco-methylthioninium

Depression

Esketamine

Diabetes

Duchenne

Epilepsy

Fenfluramine

Eye disorders

Ranibizumab

Fungal infections

HIV

Head and neck cancer

Durvalumab

Headache

Hearing disorders

Hemostasis promoting medication

Hodgkin's lymphoma

Hormonal disorders

Indolent non-Hodgkin’s lymphoma

Ibrutinib

Infectious diseases other

Kidney cancer

Pembrolizumab

Leukemia

Lipid-lowering medications

Liver cancer

Durvalumab

Liver diseases

Lung cancer

Cemiplimab

Durvalumab

Lung other

Mepolizumab

Nintedanib

Lymphoma

Mesothelioma

Metabolic diseases

Multiple Myeloma

Belantamab mafodotin

Daratumumab

Isatuximab

Selinexor

Multiple sclerosis

Muscular diseases

Muscular diseases other

Myeloproliferative disorders